In recent years, biologics have been widely used in the management of moderate to severe CD, including anti-tumor necrosis factor (anti-TNF)-α agents, vedolizumab (VDZ) and ustekinumab (UST) [5]. The gene discussed is TNF; the disease is Cowden disease.